Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial

202399 citationsJournal Articlehybrid Open Access

Authors

Novel targeting of OX40L-expressing APCs with amlitelimab was well tolerated and resulted in clinically meaningful improvements in AD.

Good health and well-being

Published in: British Journal of Dermatology

Volume 189, Issue 5, pp. 531-539

Field-Weighted Citation Impact: 29.04